How Does Polymyxin B/Trimethoprim Work? Mechanism of Action Explained in Plain English

Polymyxin B/Trimethoprim (Polytrim) is an antibiotic eye drop, but it's actually two antibiotics in one — and each one kills bacteria in a completely different way. Understanding how this drug works can help you understand why it's effective, why it needs to be used for the full course, and why your doctor might choose it over other options.

Why Combine Two Antibiotics?

Bacteria that cause eye infections like pink eye come in two main categories: gram-positive (like Staphylococcus and Streptococcus) and gram-negative (like Pseudomonas and Haemophilus influenzae). Each category has a different cell wall structure, and no single antibiotic covers all of them perfectly. By combining polymyxin B (which targets gram-negatives) with trimethoprim (which targets gram-positives), Polytrim provides broad coverage against the bacteria most likely to cause bacterial conjunctivitis.

How Polymyxin B Works: Punching Holes in Bacterial Cell Walls

Polymyxin B is a cyclic lipopeptide antibiotic — a type of molecule with both water-loving and fat-loving parts that allow it to interact with bacterial cell membranes. Here's what happens when polymyxin B encounters a gram-negative bacterium:

Polymyxin B is drawn to the outer membrane of gram-negative bacteria, which contains lipopolysaccharide (LPS), a fat-like molecule unique to these bacteria.

Polymyxin B binds to the LPS and inserts itself into the outer membrane.

This disrupts the membrane's integrity — essentially punching holes in the bacterium's outer wall.

Without its protective outer membrane, the bacterium leaks its vital cellular contents and dies. This is called bactericidal activity — meaning it directly kills the bacteria, rather than just slowing their growth.

Polymyxin B is particularly effective against Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, and H. influenzae — all gram-negative organisms that can cause eye infections.

How Trimethoprim Works: Blocking Bacteria's Food Factory

Trimethoprim is an antifolate antibiotic. To understand how it works, you need to know one thing: bacteria must make their own folic acid (a B-vitamin) to survive. They can't get it from their environment — they have to manufacture it themselves using an enzyme called dihydrofolate reductase (DHFR). Here's where trimethoprim steps in:

Trimethoprim mimics the normal substrate of the DHFR enzyme and binds tightly to it.

By blocking DHFR, trimethoprim shuts down the bacterium's folic acid production line.

Without folic acid, the bacterium can't synthesize DNA, RNA, or the proteins it needs to grow and reproduce.

The bacterium essentially starves for a vital nutrient and can no longer multiply. This is called bacteriostatic activity — it stops bacterial growth and lets your immune system clear the infection.

An important note: trimethoprim's DHFR binding is roughly 50,000 times more potent for bacterial DHFR than for human DHFR. This is why it selectively kills bacteria without significantly harming your own cells — and especially why the topical ophthalmic version has an excellent safety profile.

Why Does the Drug Need a Full 7–10 Day Course?

Even though your eye may look significantly better after 2–3 days, bacteria are still present. Stopping the antibiotic early leaves surviving bacteria — the ones that tolerated the first few doses best — free to multiply. These are more likely to be resistant strains. By completing the full 7–10 days, you ensure that even the hardiest remaining bacteria are cleared from the eye.

Why Is the Drug Applied Topically (to the Eye) Rather Than Taken by Mouth?

Topical application achieves very high drug concentrations exactly where they're needed (the eye surface) with minimal systemic absorption. Blood samples taken from human volunteers after instilling Polymyxin B/Trimethoprim showed negligible systemic levels. This targeted approach maximizes effectiveness against ocular bacteria while minimizing the risk of whole-body side effects. Polymyxin B given systemically (by IV) has significant kidney toxicity — topical application avoids this entirely.

The Bottom Line

Polymyxin B/Trimethoprim works through two complementary mechanisms — cell membrane disruption and folic acid blockade — that together provide broad coverage against the bacteria most likely to cause eye infections. Understanding the science behind the drug reinforces why completing the full course matters. For a practical patient guide covering dosage and usage, see what is Polymyxin B/Trimethoprim.